Characteristic | Hemato-oncologic patients (N = 103) n (%) | Healthy subjects (N = 103) n (%) | OR 95% CI | P value |
---|---|---|---|---|
Colonized by GNB | 36 (34.9) | 18 (17.5) | 2.53 (1.32–4.86) | 0.007 * |
Clinically relevant GNB isolated ‡ | 15 (14.5) | 5 (4.8) | 3.34 (1.16–9.56) | 0.03 * |
GNB isolated | ||||
Klebsiella spp. | 18 (17.5) | 8 (7.8) | 2.51 (1.04–6.07) | 0.05 * |
Enterobacter spp. | 3 (2.9) | 5 (4.8) | 0.58 (0.13–2.52) | 0.72 † |
Citrobacter spp. | 5 (4.8) | 1 (0.9) | 5.2 (0.59–45.34) | 0.21 † |
Escherichia coli | 5 (4.8) | 1(0.9) | 5.2 (0.59–45.34) | 0.21 † |
Pseudomonas spp. | 3 (2.9) | 1(0.9) | 3.06 (0.31–29.91) | 0.62 † |
Stenotrophomonas maltophilia | 1 (0.9) | 2 (1.9) | 0.49 (0.04–5.54) | 1 † |
Acinetobacter sp. | 1 (0.9) | 0 | - | 1 † |
Colonized by resistant GNB | 12 (11.6) | 0 | 28.3 (1.65-484.33) | < 0.001 * |
Type of colonizing-resistant bacteria ESBL | 2 (1.9) | - | - | - |
AmpC B-lactamase | 2 (1.9) | - | - | - |
MDR | 4 (3.8) | - | - | - |
MDR and ESBL | 1 (0.9) | - | - | - |
Resistant to 1 antimicrobial group | 3 (2.9) | - | - | - |